{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:31:08Z","timestamp":1793370668128,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abbott Products Operations AG"},{"name":"Allschwil"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Is exposure to dydrogesterone a risk factor for congenital anomalies when given in the first trimester for recurrent\/threatened pregnancy loss or as luteal support in assisted reproductive technology (ART)?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Dydrogesterone, when given in the first trimester for recurrent\/threatened pregnancy loss or as luteal support in ART, is not a relevant additional risk factor for congenital anomalies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Despite large clinical trials and meta-analyses that show no association between dydrogesterone and congenital anomalies, some recently retracted publications have postulated an association with teratogenicity. Dydrogesterone is also often rated as less safe than bioidentical progestins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>A systematic review was conducted according to a pre-specified protocol with searches on Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Clinicaltrials.gov. The search was limited to human studies, with no restrictions on language, geographical region, or date. The search algorithm used a PICO (Population, Intervention, Comparison, Outcome)-style approach combining both simple search terms and medical subject heading terms. As congenital anomalies are mostly reported as secondary outcomes, the search term \u2018safety\u2019 was added.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Interventional study and observational study (OS) designs were eligible for inclusion. Inclusion criteria were: women &amp;gt;17\u2009years old treated for threatened miscarriage, recurrent pregnancy loss, and\/or ART; the use of dydrogesterone in the first trimester compared with placebo, no treatment or other interventions; and reporting of congenital anomalies in newborns or infants \u226412\u2009months old (primary outcome). Two authors (A.K., M.R.N.) independently extracted the following data: general study information, study population details, intervention and comparator(s), and frequencies of congenital anomalies (classification, time of determination, and type). Risk of bias focused on the reporting of congenital malformations and was assessed using the Cochrane Risk of Bias Tool Version 2 or the ROBINS-I tool. The GRADEproGDT platform was used to generate the GRADE summary of findings table.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Of the 897 records retrieved during the literature search, 47 were assessed for eligibility. Nine studies were included in the final analysis: six randomized controlled trials (RCTs) and three OSs. Among the RCTs, three had a low risk and three a high risk of bias. Two of the OSs were considered to have a serious risk of bias and one with critical risk of bias and was excluded for the evidence syntheses. The eight remaining studies included a total of 5070 participants and 2680 live births from 16 countries. In the meta-analysis of RCTs only, the overall risk ratio (RR) was 0.92 [95% CI 0.55; 1.55] with low certainty. When the two OSs were included, the overall RR was 1.11 [95% CI 0.73; 1.68] with low certainty.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The studies included in the analysis do not report congenital anomalies as the primary outcome; reporting of congenital anomalies was often not standardized.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>This systematic literature review and meta-analysis provide clear reassurance to both clinicians and patients that dydrogesterone is not associated with congenital anomalies above the rate that might be expected due to environmental and genetic factors. The results of this work represent the highest current level of evidence for the question of congenital anomalies, which removes the existing uncertainty caused by poor quality and retracted studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>Editorial support was provided by Highfield Communication Consultancy, Oxford, UK, sponsored by Abbott Products Operations AG, Allschwil, Switzerland. A.K., J.A.G.-V., L.P.S., J.N.v.d.A., and J.F.S. received honoraria from Abbott for preparation and participation in an advisory board. J.A.G.-V. received grants and lecture fees from Merck, Organon, Ferring, Gedeon Richter, and Theramex. M.R.N. has no conflicts of interest. J.N.v.d.A. and J.A.G.-V. have no other conflicts of interest. A.K. received payment from Abbott for a talk at the IVF Worldwide congress on 22 September 2023. J.F.S. has received grants from the National Institutes of Health, royalties\/licences from Elsevier and Prescient Medicine (SOLVD Health), consulting fees from Burroughs Wellcome Fund (BWF) and Bayer, honoraria from Magee Women's Research Institute, Wisconsin National Primate Research Centre, University of Kansas and Oakridge National Research Laboratory, Agile, Daiichi Sankyo\/American Regent, and Bayer, and travel support to attend meetings for the International Academy of Human Reproduction (IAHR). J.F.S. has patents related to diagnosis and treatment of PCOS and prediction of preterm birth. J.F.S. participates on advisory boards for SOLVD Health, Wisconsin National Primate Research Centre, and FHI360, was the past President board member of the Society for Reproductive Investigation, has a leadership role for the following organizations: Scientific Advisory Board, SOLVD Health, EAB Chair for contraceptive technology initiative, FHI360, EAB member, Wisconsin National Primate Research Centre, Advisory Board for MWRI Summit, Chair of BWF NextGen Pregnancy Research Panel, Medical Executive Committee at the Howard, and Georgeanna Jones Foundation, and is Vice President, IAHR. L.P.S. has received consulting fees from Shield Pharmaceuticals, Scynexis, Organon, Natera, Celula China, AiVF, Agile, Daiichi Sankyo, American Regent, and Medicem, honoraria from Agile, Daiichi Sankyo\/American Regent, and Bayer, and travel support from BD Diagnostics. L.P.S. participates on the data safety monitoring board for Astellas and is a Chair of DSMB for fezolinetant. Abbott played no role in the funding of the study or in study design, data collection, data analysis, data interpretation, or writing of the report.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>PROSPERO 2022 CRD42022356977.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/hropen\/hoae004","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T05:53:01Z","timestamp":1706075581000},"source":"Crossref","is-referenced-by-count":19,"title":["No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0490-1554","authenticated-orcid":false,"given":"Alexander","family":"Katalinic","sequence":"first","affiliation":[{"name":"Institute for Social Medicine and Epidemiology, University of Luebeck , Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R","family":"Noftz","sequence":"additional","affiliation":[{"name":"Institute for Social Medicine and Epidemiology, University of Luebeck , Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A","family":"Garcia-Velasco","sequence":"additional","affiliation":[{"name":"IVI RMA Global Research Alliance , Madrid, Spain"},{"name":"Department of Obstetrics and Gynaecology, Rey Juan Carlos University , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee P","family":"Shulman","sequence":"additional","affiliation":[{"name":"Division of Clinical Genetics, Department of Obstetrics & Gynecology, Feinberg School of Medicine of Northwestern University , Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N","family":"van den Anker","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Children\u2019s National Hospital , Washington, DC, USA"},{"name":"Pediatric Pharmacology and Pharmacometrics Research Center, University Children\u2019s Hospital Basel , Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome F","family":"Strauss III","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2024021117593832300_hoae004-B1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00404-022-06674-2","article-title":"The optimal route of progesterone administration for luteal phase support in a frozen embryo transfer: a systematic review","volume":"308","author":"Almohammadi","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"2024021117593832300_hoae004-B2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF02070143","article-title":"Progesterone profiles in luteal-phase defects associated with recurrent spontaneous abortions","volume":"13","author":"Babalio\u011flu","year":"1996","journal-title":"J Assist Reprod Genet"},{"key":"2024021117593832300_hoae004-B3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/uog.15814","article-title":"Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Barbosa","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2024021117593832300_hoae004-B4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/0272989X9801800408","article-title":"Attitudes of obstetricians and gynecologists toward hormone replacement therapy","volume":"18","author":"Baron","year":"1998","journal-title":"Med Decis Making"},{"key":"2024021117593832300_hoae004-B5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/13697137.2018.1436166","article-title":"Progestogens and pregnancy loss","volume":"21","author":"Carp","year":"2018","journal-title":"Climacteric"},{"key":"2024021117593832300_hoae004-B6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/humrep\/deaa327","article-title":"Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial","volume":"36","author":"Chan","year":"2021","journal-title":"Hum Reprod"},{"key":"2024021117593832300_hoae004-B7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.fertnstert.2006.07.1506","article-title":"Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone","volume":"87","author":"Czajkowski","year":"2007","journal-title":"Fertil Steril"},{"key":"2024021117593832300_hoae004-B8","first-page":"CD013792","article-title":"Progestogens for preventing miscarriage: a network meta-analysis","volume":"4","author":"Devall","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2024021117593832300_hoae004-B9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jsbmb.2005.08.007","article-title":"Dydrogesterone in the reduction of recurrent spontaneous abortion","volume":"97","author":"El-Zibdeh","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2024021117593832300_hoae004-B10","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.maturitas.2009.11.013","article-title":"Dydrogesterone support in threatened miscarriage","volume":"65","author":"El-Zibdeh","year":"2009","journal-title":"Maturitas"},{"key":"2024021117593832300_hoae004-B11","author":"ESHRE","year":"2022"},{"key":"2024021117593832300_hoae004-B12","author":"EUROCAT","year":"2023"},{"key":"2024021117593832300_hoae004-B13","first-page":"2212","article-title":"Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial","volume":"33","author":"Griesinger","year":"2018","journal-title":"Hum Reprod"},{"key":"2024021117593832300_hoae004-B14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rbmo.2018.11.017","article-title":"Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction","volume":"38","author":"Griesinger","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2024021117593832300_hoae004-B15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/0272989X221140803","article-title":"The naturalness bias influences drug and vaccine decisions across cultures","volume":"43","author":"Ji","year":"2023","journal-title":"Med Decis Making"},{"key":"2024021117593832300_hoae004-B16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.rbmo.2022.03.032","article-title":"A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis","volume":"45","author":"Katalinic","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2024021117593832300_hoae004-B17","doi-asserted-by":"crossref","first-page":"101496","DOI":"10.1016\/j.jenvp.2020.101496","article-title":"For the love of nature: People who prefer natural versus synthetic drugs are higher in nature connectedness","volume":"71","author":"Li","year":"2020","journal-title":"J Environ Psychol"},{"key":"2024021117593832300_hoae004-B18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1471-0528.2000.tb11670.x","article-title":"Endocrinological and endometrial factors in recurrent miscarriage","volume":"107","author":"Li","year":"2000","journal-title":"BJOG"},{"key":"2024021117593832300_hoae004-B19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0015-0282(98)00515-9","article-title":"Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study","volume":"71","author":"Licciardi","year":"1999","journal-title":"Fertil Steril"},{"key":"2024021117593832300_hoae004-B20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12687-018-0384-2","article-title":"Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide","volume":"9","author":"Moorthie","year":"2018","journal-title":"J Community Genet"},{"key":"2024021117593832300_hoae004-B21","author":"Mount Sinai Health Library","year":"2023"},{"key":"2024021117593832300_hoae004-B22","doi-asserted-by":"crossref","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI\u2020","volume":"2020","author":"Ovarian Stimulation TEGGO","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2024021117593832300_hoae004-B23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024021117593832300_hoae004-B24","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.maturitas.2009.11.016","article-title":"Dydrogesterone in threatened miscarriage: a Malaysian experience","volume":"65","author":"Pandian","year":"2009","journal-title":"Maturitas"},{"key":"2024021117593832300_hoae004-B25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.12669\/pjms.37.3.3700","article-title":"Oral versus vaginal micronized progesterone for the treatment of threatened miscarriage","volume":"37","author":"Parveen","year":"2021","journal-title":"Pak J Med Sci"},{"key":"2024021117593832300_hoae004-B26","author":"Retraction Watch Database","year":".."},{"key":"2024021117593832300_hoae004-B27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.steroids.2011.02.043","article-title":"Selectivity and potency of the retroprogesterone dydrogesterone in vitro","volume":"76","author":"Ri\u017ener","year":"2011","journal-title":"Steroids"},{"key":"2024021117593832300_hoae004-B28","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.maturitas.2009.10.011","article-title":"Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium","volume":"65","author":"Schindler","year":"2009","journal-title":"Maturitas"},{"key":"2024021117593832300_hoae004-B29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","article-title":"Classification and pharmacology of progestins","volume":"61","author":"Schindler","year":"2008","journal-title":"Maturitas"},{"key":"2024021117593832300_hoae004-B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12958-021-00696-2","article-title":"A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys","volume":"19","author":"Shoham","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2024021117593832300_hoae004-B31","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2024021117593832300_hoae004-B32","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024021117593832300_hoae004-B33","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2024021117593832300_hoae004-B34","author":"The GRADE Working Group","year":"2013"},{"key":"2024021117593832300_hoae004-B35","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/humrep\/dex023","article-title":"A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization","volume":"32","author":"Tournaye","year":"2017","journal-title":"Hum Reprod"},{"key":"2024021117593832300_hoae004-B36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41073-016-0008-5","article-title":"Propagation of errors in citation networks: a study involving the entire citation network of a widely cited paper published in, and later retracted from, the journal Nature","volume":"1","author":"van der Vet","year":"2016","journal-title":"Res Integr Peer Rev"},{"key":"2024021117593832300_hoae004-B37","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/humrep\/deab093","article-title":"Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study","volume":"36","author":"Vuong","year":"2021","journal-title":"Hum Reprod"},{"key":"2024021117593832300_hoae004-B38","doi-asserted-by":"crossref","first-page":"102110","DOI":"10.1016\/j.jogoh.2021.102110","article-title":"Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle","volume":"50","author":"Xu","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2024021117593832300_hoae004-B39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00246-015-1190-9","article-title":"The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy","volume":"36","author":"Zaqout","year":"2015","journal-title":"Pediatr Cardiol"}],"container-title":["Human Reproduction Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hropen\/advance-article-pdf\/doi\/10.1093\/hropen\/hoae004\/56353119\/hoae004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2024\/1\/hoae004\/56660163\/hoae004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2024\/1\/hoae004\/56660163\/hoae004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T18:00:07Z","timestamp":1707674407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hropen\/article\/doi\/10.1093\/hropen\/hoae004\/7587439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/hropen\/hoae004","relation":{},"ISSN":["2399-3529"],"issn-type":[{"value":"2399-3529","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"hoae004"}}